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Abstract
Background: Zambia is currently experiencing an epidemiological transition, from communicable to non-communicable
diseases. The annual rate of physician-diagnosed asthma is estimated at 3 %. However, the general public’s knowledge
of asthma symptoms and signs, and their perception of asthma remain unknown. A survey was conducted aiming to
determine knowledge and perceptions of asthma among Zambians.
Methods: Adults and adolescents attending four clinics in the capital, Lusaka, were surveyed using a standardized
questionnaire from July 2011 to March 2012.
Results: Data from 1,540 participants (mean age 30.7 years, 65 % female) were collected. Most patients (74 %) were
living in low-cost housing. One hundred and sixteen (7.6 %) participants reported either a medical diagnosis of asthma
or currently taking asthma medications. The most frequent asthma symptoms reported were wheezing (88 %), and
waking up at night with either shortness of breath (85 %), chest tightness (85 %), or cough (67 %). Medications used to
treat asthma were mostly oral short-acting beta-agonists (SABA) (59 %), inhaled SABA (30.2 %) and antibiotics (29.8 %).
Inhaled steroids were only used by 16.4 % while less than 1 % were on long-acting beta-agonists (LABA). Many
misconceptions were identified among the entire surveyed population with only 54.7 % believing hospitalisations
are not preventable, 54.7 % believing asthma symptoms can be prevented with the right medications and 37 %
believing inhalers are addictive. Nearly 60 % thought that people with asthma cannot exercise or play hard.
Significantly more individuals with asthma compared to those without thought tablets are better than inhalers
for the treatment of asthma (46 % vs 30 %).
Conclusions: We conclude that knowledge on asthma is poor in Zambia, where there remains many misconceptions
on asthma and its management.
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Background
Asthma is a serious global health problem that affects
people of all backgrounds and ages. The 2010 Global
Burden of Disease study estimates the current asthma
burden to be greater than 334 million which is consistent
with previous reports [1, 2]. Asthma prevalence within a
population generally varies between 1 %–18 % for children
and adults, with great heterogeneity between countries
[3]. Despite the paucity of data from Africa, evidence sug-
gests that prevalence rates have been steadily increasing
over the past two decades with current rates ranging from
6–20 % in Sub-Saharan Africa [4, 5].
Zambia, a landlocked country in southern Africa with
a population of 13 million is currently experiencing an
epidemiological transition, from communicable to non-
communicable diseases (NCD) [6]. The World Health
Organisation’s (WHO) World Health Survey estimated
annual rates of physician-diagnosed asthma in Zambia
to be 3 %, clinical asthma to be 3 % and wheezing symp-
toms to be 6 % [7]. These figures may underestimate the
true prevalence of asthma. In our experience treating
patients in Zambia for nearly two decades, we have
found that asthma tends to either be underdiagnosed
or mislabelled as ‘bronchitis’, especially in children.
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We believe these practices have contributed to a general
lack of knowledge and misconceptions about asthma, as
well as stigmatisation of individuals with asthma.
In Zambia, the general population’s knowledge of asthma
signs, symptoms and medication use has never been sys-
tematically investigated. Similarly, little is known about the
public’s perception of asthma as a disease. In other popula-
tions, such studies have shown that parents of children
with asthma and individuals suffering from asthma may
have poor knowledge or misconceptions about asthma and
its treatment. Common misconceptions in these studies
included the idea that asthma is contagious, that it can be
cured, that inhalers are either addictive or are not good
treatment, that herbs play a role in asthma treatment
and that asthma limits exercise [8–12]. Additionally,
there were gaps in knowledge of important asthma
symptoms such as shortness of breath, chest tightness
and nocturnal cough [9, 12].
Poor understanding of the disease can result in under-
utilisation of available health services and reduced adher-
ence to medication [13, 14]. Ultimately this leads to poorly
controlled asthma and negatively impacts quality of life.
We hypothesised that understanding of asthma in
Zambia is poor and we sought to evaluate the knowledge
and perceptions of asthma and the medications used to
treat the disease amongst patients attending primary
health care clinics.
Methods
This was a cross-sectional survey conducted in Lusaka,
Zambia, over a 9-month period, from July 2011 to March
2012. The research protocol was approved by the Univer-
sity of Zambia Biomedical Research Ethics Committee.
Survey instrument
The study questionnaire was based on the Chicago Com-
munity Asthma Survey (CCAS-32), a previously validated
instrument specifically designed to assess the knowledge,
attitudes and perceptions of asthma among the general
public [15]. Briefly, the CCAS-32 questionnaire consists
of 21 dichotomous items (“true/false” or “yes/no”) and
11 Likert-scale item (“1, never true; 2, rarely true; 3,
sometimes true; 4, often true; and 5, always true”). The
survey captures insight into nine content domains related
to asthma and its management: (1) symptoms; (2) stigma/
acceptability; (3) seriousness/severity; (4) perceptions of
susceptibility; (5) consequences; (6) barriers to care; (7)
perceptions of quality of life; (8) treatment/utilization
of health care; and (9) triggers/environmental risk. Know-
ledge levels are largely captured through the dichotomous
items, and attitudes and perceptions are mostly captured
through the Likert-scale items. Study staff administered
the questionnaire verbally in the participants’ choice of
language (either English or Nyanja, a local dialect which is
the most widely spoken local language in Lusaka). Demo-
graphic data were collected at the time of the survey and
included age, gender, education, income, occupation, area
of residence and type of housing (i.e., low, medium, or
high-cost housing; this item is used as a proxy for socio-
economic status by the Zambia Central Statistical Office).
Knowledge and attitudes of asthma relating specifically to
medication use were also assessed.
Study sites and participants
The study took place at 4 urban, Government-managed
health centres located across the city of Lusaka. Each
clinic serves a catchment area ranging from 30,000 to
50,000 people. These are “first level” clinics typical of
those where the majority of the urban population seeks
medical care [16].
Individuals ten years of age and older who were nor-
mally cared for at the four study sites during the study
period were consecutively invited to participate. Written
informed consent was obtained from both the adult
participants themselves and the guardians/parents of the
children who participated. Exclusion criteria were refusal
to give consent or inability to communicate verbally
in English or Nyanja, the most widely spoken local
language in Lusaka.
Data analysis
The sample size was estimated a priori. Given that the
population of Lusaka residents attending the urban
clinics was 810,000 [16], we assumed that the level of
asthma knowledge was 50 %. Using a margin of error of
3 % and 95 % confidence level, the minimum sample size
was calculated at 1,063 respondents. Data from the
questionnaire was extracted and analysed using SPSS 17
for Windows. Each categorical item from the question-
naire was summarized by frequency count. Likert-scale
items were converted to true/false items as per the
following: False (1 - never true; 2 - rarely true; 3 -
sometimes true) and True (4 - often true; and 5 - always
true). Socio-economic status and educational background
were analysed as outcome variables. All data were qual-
ity controlled centrally and a homogeneous template to
translate all coding was applied. Variables were then
double-checked by the principal investigator, and values
that were considered as potential errors or outliers were
individually discussed and confirmed, or removed. Com-
prehensive tabulations with ranges, mean and standard
deviation of all quantitative variables, and percentages of
all qualitative variables, were conducted. Prevalences were
presented as percentages with a 95 % confidence interval.
Differences within groups were compared using Chi-
squared tests for categorical variables, and Student t test
for continuous variables. A p-value lower than 0.05 was
considered statistically significant.
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Results
Data were collected from 1,540 participants, which rep-
resented 99 % of individuals who were invited to partici-
pate. The primary reasons for refusal to participate were
mistrust of what would be done with the information
gathered and concern for delay in receiving medical
care. Demographic characteristics of study participants
are shown in Table 1. Mean age was 30.7 years and
65 % were female. Nearly three-quarters of participants
lived in low-cost housing and 8 % lived in high-cost
housing. Twenty-three percent of participants reported
an education level up to primary education, 55 % re-
ported they had received secondary education, and 19 %
reported higher than secondary education levels. One-
hundred and sixteen (7.6 %) participants reported that
they either had been diagnosed with asthma or were cur-
rently taking asthma medications. Compared with the
participants without asthma, individuals with asthma
(either diagnosed or self-reported) were older (mean age
37.4 years, p < 0.001). There were no statistical differences
by gender, residential area, educational, employment or
economic status.
Table 1 Demographic characteristics of all participants and those with asthma (either diagnosed or treated self-report)
All
n (%)





1,540 (100 %) 116 (7.6 %) 1,417 (82.4 %)
Male 538 (35.1) 39 (33.6) 499 (35.2) 0.762
Age in years, mean ± SD 30.7 ± 12.3 37.4 ± 17.4 30.2 ± 11.6 <0.001
Age interval
10–19 years old 228 (14.9) 10 (18.6) 218 (15.4) <0.001
20–29 years old 612 (39.9) 38 (32.8) 574 (40.5)
30–39 years old 413 (27.0) 30 (25.9) 383 (27.0)
40–49 years old 153 (10.0) 12 (10.3) 141 (10.0)
50–59 years old 74 (4.8) 11 (9.5) 63 (4.4)
60–69 years old 28 (1.8) 6 (5.2) 22 (1.6)
70 years and older 24 (1.6) 9 (7.8) 15 (1.1)
Residential area
Low cost 1132 (74.0) 84 (72.4) 1048 (74.2) 0.917
Medium cost 274 (17.9) 22 (19.0) 252 (17.8)
High cost 123 (8.0) 10 (8.6) 113 (8.0)
Educational attainment
No education 26 (2.6) 7 (6.1) 19 (2.1) 0.088
Some primary 104 (10.4) 11 (9.6) 93 (10.5)
Completed primary 128 (12.8) 18 (15.7) 110 (12.4)
Some secondary 334 (33.4) 41 (35.7) 293 (33.1)
Completed secondary 218 (21.8) 18 (15.7) 200 (22.6)
More than secondary 189 (18.9) 20 (17.4) 169 (19.1)
Employment/student status
Formally employed 218 (21.5) 29 (25.0) 189 (21.0) 0.597
Self employed 262 (25.8) 25 (21.6) 237 (26.4)
In school/College/University 177 (17.4) 19 (16.4) 158 (17.6)
A dependant 358 (35.3) 43 (37.1) 315 (35.0)
Economic band (USD)
Less than $100 123 (26.1) 16 (30.2) 107 (25.6) 0.910
$100–$199 135 (28.7) 16 (30.2) 119 (28.5)
$200–$399 103 (21.9) 11 (20.8) 92 (22.0)
$400–$999 90 (19.1) 8 (15.1) 82 (19.6)
Greater than $1,000 20 (4.2) 2 (3.8) 18 (4.3)
*All statistical comparisons were performed with Chi2 tests, except for age which was performed with student t test
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Symptom frequency and treatment patterns among
the 116 individuals with asthma are shown in Table 2.
The most frequent asthma symptoms reported were
wheezing (n = 102: 88 %) and waking up at night with
either shortness of breath (n = 99: 85 %), chest tightness
(n = 99: 85 %), or cough (n = 78: 67 %). There were no
statistically significant differences by gender. In all, 82 %
of male and 75 % of female individuals with asthma re-
ported currently taking some form of asthma medication.
Medications used to treat asthma in male and female indi-
viduals, respectively were oral short-acting beta-agonists
(SABA): [71.1 % vs. 53.9 % p = 0.006], antihistamines
(7.7 % vs. 20.8 % p = 0.11), oral steroids (7.7 % vs.
15.6 % p = 0.199), theophyllines (5.2 % vs. 22.4 % p = 0.06)
and antibiotics (35.9 % vs. 33.8 % p = 0.528). Aside from
inhaled SABA, other inhaled medications were used less
often: SABA (41.0 % vs. 24.7 % p = 0.131), inhaled steroids
(18.2 % vs. 10.4 %, p = 0.032), and long-acting beta-
agonists (LABA) (2.6 % vs. 0 % p = 0.33). No participants
reported use of inhaled LABA/steroid combination.
Attitudes and perceptions among study participants
relating to asthma and its management are shown in
Table 3. Significantly more individuals with asthma knew
the signs of asthma compared to those without asthma,
including knowledge that signs included shortness of
breath (92.2 % vs 77.1 %), tightness in the chest (90.5 %
vs 75.1 %) and wheezing after exercise (91.4 % vs 77.7 %).
In addition, more individuals with asthma compared with
those without knew that asthma cannot be cured (68.1 %
vs 41.3 %). Just over seventy-six percent of the surveyed
population understood that inhalers were good treatment
for asthma. With regards to physical exercise, a substantial
number of all the participants surveyed (57.6 %) thought
that individuals with asthma cannot exercise or play hard,
with no significant difference between those with and
without asthma.
Concerning asthma perceptions, only 36.9 % of the
entire study population reported that hospitalisations for
asthma were preventable and 54.7 % believed asthma
symptoms could be prevented with medications. With
regards to perceptions towards inhaled medication, 37 %
of the study participants believed the latter were addict-
ive, with no difference between those with and without
asthma. A significant number of individuals with asthma
compared with those without (45.7 vs 30.0 %) thought
oral tablets were better than inhalers for asthma treat-
ment. Overall, 60.4 % of participants agreed that asthma
is a serious health problem in Zambia. Misconceptions








Current symptoms n (%) n (%) n (%)
Have you had wheezing or whistling in your chest at any time in the last 12 months? 102 (87.9) 35 (89.7) 67 (87.0) 0.771
Have you been at all breathless when the wheezing noise was present? 96 (82.8) 31 (88.6) 65 (97.0) 0.177
Have you had this wheezing or whistling when you did not have a cold? 44 (37.9) 13 (38.2) 31 (46.3) 0.526
Have you woken up with a feeling of tightness in your chest at any time in the last 12 months? 99 (85.3) 32 (82.1) 67 (87.0) 0.580
Have you been woken by an attack of coughing at any time in the last 12 months? 78 (67.2) 24 (61.5) 54 (70.1) 0.405
Have you been woken up by an attack of shortness of breath at any time in the last 12 months? 99 (85.3) 33 (84.6) 66 (85.7) 1.000
Have you had an attack of asthma in the last 12 months? 112 (96.6) 38 (97.4) 74 (96.1) 1.000
Are you currently taking any medicine for asthma? 89 (76.7) 32 (82.1) 57 (75.0) 0.483
Oral medication
Steroids 15 (12.9) 3 (7.7) 12 (15.6) 0.199
Theophylline 19 (16.4) 2 (5.2) 17 (22.4) 0.060
SABA 68 (58.6) 27 (71.1) 41 (53.9) 0.006
Anti-histamine 19 (16.4) 3 (7.7) 16 (20.8) 0.110
Cough mixture 9 (7.8) 0 (0.0) 9 (11.7) 0.085
Antibiotics 40 (34.4) 14 (35.9) 26 (33.8) 0.528
Inhaled medication
Steroids 19 (16.4) 11 (18.2) 8 (10.4) 0.032
SABA 35 (30.2) 16 (41.0) 19 (24.7) 0.131
LABA 1 (0.9) 1 (2.6) 0 (0.0) 0.330
*All statistical comparisons were performed with Chi2 tests
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on asthma knowledge and perceptions about the disease
in those individuals with asthma (self-reported) were
common (Table 4).
Rates of health professional-diagnosed and self-reported
asthma are shown in Fig. 1. The observed frequency of
7.6 % (95 % C.I. 6.2–9.0) was homogeneous from ado-
lescence up to age 50 years, with no differences by gender.
In older participants, the observed frequency of asthma
increased substantially to 20.6 %, more so in women than
in men (27.4 % vs 14 %).
Discussion
This study describes, for the first time knowledge and per-
ceptions of asthma in Zambia. We found that knowledge









Is shortness of breath a sign of asthma? 803 (78.8) 107 (92.2) 696 (77.1 %) <0.001
Is tightness in the chest a sign of asthma? 783 (76.8) 105 (90.5) 678 (75.1 %) <0.001
Are severe headaches a sign of asthma? 339 (33.3) 42 (36.2) 297 (32.9 %) 0.466
Is a cough at night a sign of asthma? 522 (51.2) 66 (56.9) 456 (50.5) 0.201
Is wheezing after exercise a sign of asthma? 808 (79.3) 106 (91.4) 702 (77.7) <0.001
Asthma cannot be cured. 452 (44.4) 79 (68.1) 373 (41.3) <0.001
An inhaler is a good treatment for Asthma. 778 (76.4) 84 (72.4) 694 (76.9) 0.296
People with asthma cannot exercise or play hard. 586 (57.6) 67 (57.8) 519 (57.5) 1.000
When a person with asthma is doing well they do not need to go to the doctor. 286 (28.1) 36 (31.0) 250 (27.7) 0.444
Asthma is a common reason for many school absences. 598 (58.7) 68 (58.6) 530 (58.7) 1.000
When asthma attacks stop, you don’t have asthma anymore. 240 (23.6) 16 (13.8) 224 (24.9) 0.007
You can’t have asthma as an adult without having it as a child. 291 (28.6) 17 (14.7) 274 (30.3) <0.001
Hospitalizations for asthma are preventable. 376 (36.9) 45 (38.8) 331 (36.7) 0.085
Asthma symptoms can be prevented with the right medications. 556 (54.7) 63 (54.3) 493 (54.7) 0.141
Asthma is a serious health problem in Zambia. 614 (60.4) 83 (71.5) 531 (58.9) 0.080
Asthma care is expensive. 354 (34.8) 44 (37.9) 310 (33.8) 0.738
When a person has an asthma attack they should see a doctor immediately. 873 (85.8) 104 (89.7) 769 (85.4) 0.021
University Teaching Hospital is the best place to get treated for an asthma attack. 401 (39.5) 40 (34.5) 361 (40.1) 0.005
People can become addicted to inhalers for asthma treatment. 386 (37.0) 50 (43.1) 336 (37.1) 0.355
Tablets are better than inhalers for asthma treatment. 323 (31.8) 53 (45.7) 270 (30.0) 0.003
African doctors can cure asthma. 17 (1.7) 1 (0.9) 16 (1.7) 0.673
*All statistical comparisons were performed with Chi2 tests









Asthma cannot be cured 52 (61.9) 19 (86.4) 8 (80.0) 0.063
When asthma attacks stop, you don’t have asthma anymore. 14 (16.7) 1 (4.5) 1 (10.0) 0.319
You can’t have asthma as an adult without having it as a child. 16 (19.0) 1 (4.5) 0 (0.0) 0.090
Is shortness of breath a sign of asthma? 81 (96.4) 18 (81.8) 8 (80.0) 0.024
Is tightness in the chest a sign of asthma? 79 (94.0) 19 (86.4) 7 (70.0) 0.038
Is wheezing after exercise a sign of asthma? 77 (91.7) 20 (90.9) 9 (90.0) 0.981
When a person has an asthma attack they should see a doctor immediately. 74 (88.1) 22 (100.0) 8 (80.0) 0.448
University Teaching Hospital is the best place to get treated for an asthma attack. 31 (36.9) 7 (31.8) 2 (20.0) 0.545
Tablets are better than inhalers for asthma treatment. 42 (50.0) 6 (36.4) 3 (30.0) 0.302
*All statistical comparisons were performed with Chi2 tests
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about asthma is generally poor and we identified mis-
conceptions about inhaled medications that are com-
parable with findings from other developing countries
[8, 10, 11]. Individuals with asthma were significantly
more knowledgeable on asthma signs than those without,
which is not surprising and is consistent with other stud-
ies [17, 18]. However, even individuals with asthma dem-
onstrated numerous knowledge gaps and misconceptions
relating to disease characteristics, asthma management
and quality of life. Such attitudes can have a negative
impact on patient care and quality of life [19, 20].
Misconceptions were identified regarding inhaled medi-
cations. While the majority of individuals with asthma
thought inhalers are a good treatment for asthma, many
asthmatics reported that inhalers are addictive and inferior
in efficacy to tablets. Our finding that inhaled medications
were perceived to be addictive has also been reported by
others with rates ranging from 37–48 % [11, 13, 21]. This
misconception could have a negative impact on adherence
to medication and asthma control. It has also been impli-
cated in the preference of treatment towards oral rather
than inhaler medications [11, 22]. Indeed, our study found
that most individuals with asthma were currently taking
oral SABA medications, closely followed by inhaled
SABA. Only a small proportion of patients were on
inhaled steroids. Although antibiotics do not form part of
the routine management of asthma, they were the second
most administered oral medication, reflecting either a cul-
ture of over prescription by physicians or the unregulated
access to ‘over the counter’ antibiotics in commercial
pharmacies. It is not uncommon for antibiotics to be
perceived as an important aspect of asthma treatment in
developing countries [23].
International asthma guidelines state that effective man-
agement of asthma requires a self-management approach
encompassing a strong partnership between the patients
and the health care workers [24]. In this model, patients
should be empowered to gain the knowledge, confidence,
and skills to assume a major role in the management of
their asthma. A self-management approach has been
shown to reduce asthma morbidity. Conversely, poor
self-control is likely to result if the patient has miscon-
ceptions about their asthma and inhaled medication [25].
Similarly, these guidelines also advocate the use of regu-
lar prophylactic inhaled medication to prevent symptoms
of chronic asthma, and regular bronchodilator therapy as
required for symptomatic relief [26]. Inhaled corticoste-
roids have also been shown to be effective in developing
Fig. 1 Prevalence rates of asthma (diagnosed or treated self-report) by gender and age band
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countries, reducing hospital admissions and emergency
room visits by up to 80 % [27, 28]. A study in Zambia
many years ago showed a reduction in asthma admissions
when inhaled therapy was used [29]. Despite this evidence,
up until 2013 the Zambian Standard Treatment Guide-
lines (STG), a set of nationally endorsed treatment guide-
lines covering various medical conditions used by health
workers in the public health sector, emphasized the use
of oral therapy as first line for mild cases of asthma
with inhaled therapy reserved for acute severe exacer-
bations [30]. These guidelines were silent on the use of
prophylactic inhaled steroids for prevention of chronic
asthma symptoms.
The lack of inhaled medications in the Zambian STGs
may have resulted in inconsistent availability of metered
dose inhalers (MDIs) in the public health sector, and
could have been a contributing factor to patients’ inclin-
ation toward oral medications for asthma management.
Another reason could be failure by clinicians to prescribe
MDIs due to concerns about their intermittent availability
and prohibitive cost to patients [31]. Conversely, clinicians
in the developing world may lack the knowledge on what
medications to use for asthma treatment, commonly pre-
scribing oral SABA and oral steroid for long-term man-
agement [32, 33]. Ultimately, even when physicians do
prescribe inhaled medications, some patients may just
prefer the oral route due to various negative preconceived
ideas about MDIs [34].
Finally, our finding of a much higher frequency of
asthma in adults older than 50 years is based on a small
sample size and should be interpreted with caution. It
may also be attributed to the mis-diagnosing of other
conditions that present with similar symptoms to asthma
such as chronic obstructive pulmonary disease (COPD)
and bronchiectasis [35, 36]. Interestingly, a similar in-
crease in asthma symptoms among the female population
has recently been reported in Burkina Faso [37].
Limitations of the current study
The asthma prevalence estimate of 7.6 % found in this
study is lower than the observed prevalence rates of
between 10–20 % found in other urban centres within
Sub-Saharan Africa and could be an underestimate since
it is based on self-reporting [5]. Misclassification of dis-
ease is a concern in Zambia where health workers often
mislabel asthma as ‘bronchitis’ and could also result in
under estimation of the asthma prevalence. The collec-
tion of information in English and Nyanja could have
affected study results since it is challenging to accurately
translate some technical terms related to asthma. It is
our impression that some patients do not learn the
names of the medications they are taking and this could
have possibly affected their reporting of the medications
they use.
Implications and next steps
There remain major challenges in fully understanding
the epidemiology of chronic airway diseases in Zambia
and other African countries. Trends towards urbanisa-
tion and westernisation of African countries seem to be
important contributors to the development of asthma
[38]. The findings of this study including the observation
that misconceptions about asthma are prevalent, could
provide an evidence backed basis for the development
of programmes designed to change asthma perceptions
among both health workers and the community at large.
In Zambia, the national treatment guidelines for asthma
have recently been updated (in 2013) and now recom-
mend inhaled medications as the primary treatment op-
tion for individuals with asthma, but this is not yet widely
practiced. Alongside this major improvement, however,
oral SABAs are still recommended as an alternative treat-
ment option. The STG update will ensure the provision of
free and consistent supply of MDIs to health institutions,
avoiding cost implications on the patient. The government
and other stakeholders have important roles to play in
assuring that appropriate education of health workers
takes place so that they adhere to the new guidelines and
prescribe the drugs rationally in primary health care facil-
ities [39]. Ultimately these measures would have a positive
impact on inhaler perception, use, compliance and asthma
control.
Conclusions
Knowledge about asthma is poor among Zambians and
misconceptions are prevalent. Strategies are needed to
increase education and awareness about the disease in
order to improve disease management, reduce stigma-
tisation and work towards decreasing the societal burden
of disease in Zambia.
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